|Articles|January 29, 2015

Pharma 2015: Industry in Flux

Pharma is still a 21st Century growth industry, but investment dynamics no longer favor organic growth. Check out our strategic outlook infographic.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

Pharma 2015: Industry in Flux

Related Content

Model Examples

John Oyler: Rewiring Operations in Oncology

Asembia ASX26: Building Value-Based Care Models for Cell & Gene Therapy: Q&A with Will Shrank

The Death of Deciling

Asembia ASX26: The ‘Entirely Pass-Through’ Business Model

Trending on PharmExec

Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra

John Oyler: Rewiring Operations in Oncology

Beyond the Molecule: The New Competitive Battlefield in Oncology

FDA Places Full Clinical Hold on Aardvark Therapeutics’ ARD-101

FDA Approves Fasenra for Hypereosinophilic Syndrome